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S U M M A R Y
Little is known regarding waning immunity to tetanus toxoid (TT) in HIV-infected children and the need
for booster doses before the recommended interval of 5–10 years. Anti-tetanus antibodies were assessed
by ELISA in 24 HIV-infected and 24 control children. A protective level (>0.1 IU/ml) of TT antibodies was
observed in 62% of HIV-infected children and in 100% of controls. HIV-infected children with ﬁve doses
had a signiﬁcantly (p = 0.01) lower prevalence of protective immunity compared to controls. Follow-up
anti-TT antibody levels in nine HIV-infected children declined from 1.27 to 0.26 IU/ml, but levels did not
decline in the seven controls; ﬁve of the seven (71%) children with a non-protective level of antibodies
responded with a level >0.16 IU/ml following one booster dose of the vaccine. HIV-infected children may
need TT boosters before the recommended 5–10 years.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Little evidence is available regarding the persistence of anti-
tetanus antibodies, and there are no data regarding the response to
booster doses of the tetanus toxoid (TT) vaccine, in HIV-infected
children and adolescents.1
The American Academy of Pediatrics recommends booster
doses of TT every 10 years for healthy children and adolescents, but
no speciﬁc recommendations for their HIV-infected counterparts.
The purpose of this study was to examine the persistence of
protective anti-TT antibody in HIV-infected children and to assess
responses of children with non-protective antibody to booster
doses of the vaccine.
2. Methods
The study was conducted from August 1995 to April 1997
following approval of the protocol by the Ethics Committee of the
Interfaith Medical Center in Brooklyn, New York.
A convenience sample of 20 HIV-infected children was selected.
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pertussis, and tetanus). Four of the four-dose recipients were
enrolled a second time into the study as ﬁve-dose recipients,
bringing the total number in the ﬁve-dose group to 13. A
convenience sample of 24 control children (mothers known to
be HIV-negative) matched by the number of doses of the vaccine
was recruited. Within the HIV group, 58% of children had evidence
of moderate to severe clinical (class B and C) and immunologic
(CD4 count <25% for age) disease.2
All children had received three doses of adsorbed DPT vaccine
(Connaught Labs, Inc., Swiftwater, PA, USA) as their primary series,
followed by the fourth and ﬁfth routine booster doses. Only one
child from the HIV group (98 months) had received Td (tetanus and
diphtheria) vaccine as the ﬁfth dose. The mean ages of children in
the HIV and control groups were comparable. The mean time
intervals between the vaccine doses and serologic assays were also
comparable between the two groups. Anti-TT IgG antibody was
assayed using an ELISA (Specialty Labs, Santa Monica, CA, USA). An
anti-TT level of >0.1 IU/ml was considered a correlate of
protection.3–6
Of the children possessing protective levels (>0.1 IU/ml) of TT
antibodies, nine HIV-infected and seven control children were
available for a follow-up measurement of antibody levels (Table 1).
Seven of the HIV-infected children (three from the baseline study
and four from the follow-up study) (Table 2) with non-protectiveses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline and follow-up anti-tetanus toxoid antibodies in HIV-infected and uninfected children
Groups Four-dose recipients (n = 11) Five-dose recipients (n = 13)
Baseline antibody (IU/ml),
median (range)  SD
Prevalence protection
(%)
Baseline antibody (IU/ml),
median (range)  SD
Prevalence
protection (%)
Baseline to follow-up antibody
(IU/ml) in 10 months, mean ( SD)
HIV
(n = 24)
0.66 (0.06–3.72) ( 1.20) 8/11 (73%) 0.14 (0.04–2.97) ( 0.85) 7/13 (54%) 1.27 ( 1.26) to 0.26 ( 0.21) (n = 9)
Control
(n = 24)
0.63 (0.23–2.20) ( 0.69) 11/11 (100%) 0.58 (0.20–5.54) ( 1.43) 13/13 (100%) 1.97 ( 2.03) to 1.50 ( 2.11) (n = 7)
p-Value NS NS NS 0.01a 0.03 vs. NSb
3-fold vs. no fold fall
SD, standard deviation; NS, not signiﬁcant.
a Two-tailed Fisher’s exact test.
b Two-tailed t-test.
Table 2
Booster study: HIV-infected children
Age at
vaccination,
months
Time from
vaccination to
serology, months
Baseline
anti-TT,
IU/ml
CDC class
at baseline
CD4/mm3 at
baseline
Follow-up
anti-TT, IU/ml
Time from
baseline to
follow-up,
months
CD4/mm3 at
follow-up
CDC class at
follow-up
Age at
booster,
months
Post-booster
anti-TT,
IU/mla
1. 49 30 0.14 A 1012 0.06 10 898 A 96 1.97
2. 49 8 0.14 B 8 0.05 15 672b B 73 0.41b
3. 85 41 1.6 B 807 0.06 15 4 C 141 0.05
4. 72 3 0.34 A 885 0.06 12 894 A 88 0.74
5. 57 61 0.1 B 631 NA NA 980 B 143 0.13
6. 67 2 0.1 B 662 NA NA 372 B 69 0.95
7. 35 51 0.08 A 490 NA NA 415 A 93 0.56
TT, tetanus toxoid; CDC, Centers for Disease Control and Prevention; NA, not available.
a Time from booster to serology was a mean of 1.5 months.
b Following 11 months on ritonavir.
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TT (7 years of age) followed by a reassessment of antibody levels
at a mean of 2 months post-booster.
3. Results
A signiﬁcantly (p = 0.03) higher proportion of the children with
non-protective levels (89%) showed evidence of moderate to
severe (class B–C) disease compared to those with protective levels
(40%). Two four-dose recipient children who possessed protective
levels not only had non-protective levels at an older age, but also
showed evidence of clinical disease progression. In contrast, one
child with non-protective levels developed protective levels
approximately 1 month following the ﬁfth dose after the addition
of a protease inhibitor to his antiretroviral regimen.
A considerable decline in antibodies occurred on follow-up in
the HIV-infected children compared to the control children (Tables
1 and 2). Five of the seven (71%) children with non-protective
levels responded with a level >0.16 IU/ml following one booster
dose (Table 2). At booster doses, non-responders were signiﬁcantly
(p = 0.001) older (mean age 142 months) when compared to the
responders (mean age 84 months).
4. Discussion
A protective level of an anti-tetanus antibody remains the
major factor determining protection against occurrence of this
disease.3–5 HIV-infected children and adolescents may remain at
risk of developing the disease despite adequate tetanus vaccina-
tions.7 According to a recent study, 12 out of 21 (57%) patients
diagnosed with tetanus were found to also be infected with HIV.8
Concerns also remain for HIV-infected pregnant women with
inadequate immunity to tetanus at risk of developing tetanus and
tetanus in their infants before the acquisition of vaccine-mediated
protection. Although it is apparent from this study that olderHIV-infected children had signiﬁcantly lower anti-tetanus immu-
nities compared to their control counterparts, it is however unclear
whether the non-protective levels following the ﬁfth dose were
due to the failure to mount a post-vaccination response or due to
waning antibodies. Our ﬁndings suggest that it is extremely
important to vaccinate HIV-infected children at an early age, while
the immune system is still intact.2,6 To determine the need for a
booster dose, the monitoring of TT antibody in older HIV-infected
children may be necessary following the ﬁfth dose, in appropriate
clinical settings.
With reconstitution of the immune system using highly active
antiretroviral therapy (HAART), it is possible that persistence of
immunity may be achievable without booster doses. This notion is
supported by the ﬁnding in our study demonstrating evidence of
immune reconstitution with the development of protective levels
of antibodies following the introduction of a protease inhibitor in
subject 2 (Table 2). It is recommended that further studies with a
larger sample size be conducted to replicate the results of this
study.
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